Press Releases Ypsomed Group

Burgdorf and Eindhoven (NL) – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite Digital Platform. The two companies agree to build a solution for Ypsomed’s new SmartServices™ based on Philips HealthSuite Digital Platform. The combination of Ypsomed connected self-medication devices with Philips’ HealthSuite Digital Platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services for enhanced patient outcomes.

Ypsomed partners with JDRF

Press Releases Ypsomed Group

Burgdorf/New York – JDRF, the leading global organization funding type 1 diabetes (T1D) research, has announced a partnership with Ypsomed, a Switzerland-based developer and manufacturer of injection and infusion systems, as part of JDRF’s Open-Protocol Automated Insulin Delivery (AID) Systems Initiative. The objective of the project is the development and regulatory approval of the next-generation mylife™ YpsoPump® insulin pump supporting incorporation into an automated insulin delivery (AID) system via open-protocol communication with third-party smartphone-based apps and/or other devices.

Topping-out ceremony at the new Ypsomed site in Schwerin
After completion of the building shell in the coming weeks, the interior work of the production plant will now begin.

Press Releases Ypsomed Group

Burgdorf/Schwerin - The topping-out ceremony for Ypsomed's new production plant took place on 28 June 2018. The Swiss medical technology company is building a new production plant in Schwerin's industrial park, creating around 150 new jobs in the region in the coming years. The new production plant will start operations in summer 2019.

Press Releases Ypsomed Group

Burgdorf - On 27 June 2018, the Annual General Meeting of the Ypsomed Group elected Paul Fonteyne as a new member of the Board of Directors and the Compensation Committee of the Ypsomed Group. He is Chairman of Boerhinger Ingelheim USA, and until March 2018 he was President and CEO of Boehringer Ingelheim USA. Paul Fonteyne follows Prof. em. Dr. Norbert Thom, who resigned at the 2018 Annual General Meeting.

Press Releases Ypsomed Group

Burgdorf – In the business year 2017/18, Ypsomed generated consolidated sales of CHF 466.1 million (prior year: CHF 389.6 million). Compared with the previous year, this represents an increase in sales of 19.7%. The operating results (EBIT) increased by 10.4% compared to the previous year, from CHF 55.3 million to CHF 61.1 million. Net profit increased to CHF 52.1 million (previous year: CHF 46.2 million).